加味楂曲饮对实验性非酒精性脂肪性肝病大鼠FATP4、UCP2、COXⅠ的影响  

The Impact of JiaWeiZhaQuYin on FATP4,UCP2,COXⅠ in the Experimental Non-Alcoholic Fatty Liver Disease Rats

作　　者：张传涛[1] 周道杰[2] 杨鸿[1] 郑政隆[2] 周显华[2] 

机构地区：[1]成都中医药大学附属医院,四川成都610072 [2]成都中医药大学,四川成都610075

出　　处：《时珍国医国药》2014年第6期1505-1507,共3页Lishizhen Medicine and Materia Medica Research

基　　金：国家自然科学基金(No.81102720,81202624);教育部重点项目(No.20120150);成都中医药大学科技发展基金(No.2012005)

摘　　要：目的研究中药加味楂曲饮(JWZQY)对实验性非酒精性脂肪性肝病(Non-Atcoholic Fatty Liver Diesease,NAFLD)大鼠血清游离脂肪酸(FFA)、肝组织4型脂肪酸转运蛋白(FATP4)、解偶联蛋白2(UCP2)、细胞色素C氧化酶Ⅰ(COXⅠ)的mRNA水平的影响,以揭示其作用机制。方法 SDF级大鼠随机分为4组:空白组、模型组、低剂量组、中剂量组。空白组大鼠给予基础饲料,其余给予高脂饲料造模,自造模第1天起,空白组、模型组大鼠灌服等体积生理盐水,低、中剂量组分别灌服等体积含1,2g/ml浓度JWZQY溶液,8周后,采用比色方法检测血清FFA,荧光定量PCR法检测肝组织FATP4、UCP2、COXⅠ的mRNA水平。结果与模型组比较,中剂量组FFA(1029.55±122.72VS3779.07±476.52)、UCP2mRNA(1.99±0.09VS3.14±0.15)、FATP4mRNA(1.62±0.20VS2.10±0.19)的水平明显降低,COXⅠmRNA(0.71±0.07VS 0.57±0.04)明显升高(P<0.01)。与低剂量组比较,中剂量组FFA(1029.55±122.72VS3655.04±170.82)、UCP2mRNA(1.99±0.09VS2.86±0.06)、FATP4 mRNA(1.62±0.20VS1.97±0.16)水平也明显降低,而COXⅠmRNA(0.71±0.07VS 0.62±0.06)也明显升高(P<0.05)。结论 JWZQY防治实验性非酒精性脂肪性肝病可能是通过影响COXⅠ、UCP2、FATP4改善脂肪酸转运、线粒体功能等有关。Objective To study the impact of Chinese medicine JiaWeiZhaQuYin （JWZQY） on serum free fatty acids, the mRNA of liver tissue Fatty Acid Transport Protein 4 mRNA, Uncoupling Protein 2, Cytochrome Coxidase 1 in experimental Non - Alcohol- ic Fatty Liver Disease （NAFLD） rats, to reveal its mechanism. Methods SDF rats were randomly divided into 4 groups ： blank group, model group, low dose group, middle dose group. Blank group rats were given basic feed, the rest of the group rats were given a high fat diet model, starting from the first day of the modeling, blank group, model group were fed with an equal volume of saline, low and middle dose group were fed with an equal volume containing 1 g/m1,2g/ml JWZQY solution, after 8 weeks, Colorimetric method was used to detect serum FFA, Quantitative PCR used to detect the mRNA of liver tissue FATP4 ,UCP2 and COX ] . Resuits Compared with the model group,FFA（ 1029.55 ± 122.72VS3779.07± 476.52）, UCP2mRNA （ 1.99 ± 0.09VS3.14 ± 0. 15）, FATP4mRNA（ 1.62 ± 0.20VS 2.10 ±0.19 ） were significantly decreased in middle dose group, COX I mRNA （ 0.71 ± 0. 07 VS 0.57 ±0. 04 ）was significantly increased （P 〈 0.01 ）. Compared with the low dose group, FFA （ 1029.55 ±122.72VS3655. 04 ±170.82） ,UCP2mRNA（ 1.99± 0.09VS2.86± 0.06）, FATP4 mRNA（ 1.62 ± 0.20VS1.97 ± 0.16 ） were significantly de- creased in middle dose group, COX I mRNA （0.71± 0.07VS 0.62 ± 0. 06 ） was significantly increased （ P 〈 0. 05 ）. Conclu- sion JWZQY may influence the expression of COX I mRNA, UCP2mRNA, and FATP4mRNA to interfere with experimental nonal- coholic fatty liver disease, related to fatty acid transporting, Mitoehondrial function.

关 键 词：加味楂曲饮 非酒精性脂肪性肝病 游离脂肪酸 4型脂肪酸转运蛋白 肝组织解偶联蛋白 细胞色素C氧化酶Ⅰ 

分 类 号：R285.5[医药卫生—中药学]